StockData
GT Biopharma, Inc. logo

GT Biopharma, Inc. (GTBP) shareholders

GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 5/30
$3.18−0.35 (-10.04%)

Close on Nov 17, 2026Market cap $143.45MP/E –Yield –

Ownership

Who owns GT Biopharma's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Five Narrow Lane LP253,3889.99%13G (passive)May 13, 2025
Cytovance Biologics Inc219,4579.80%13G (passive) amendmentSep 30, 2024
RainForest Partners, LLC180,2589.99%13G (passive)Sep 15, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Michael Martin BreenCEO and Director856,2181.90%Sep 8, 2025
Alan Louis UrbanChief Financial Officer––Sep 8, 2025
Charles J. CasamentoDirector––Sep 8, 2025
Hilary KramerDirector––Sep 8, 2025
David C. Mun-GavinDirector––Sep 8, 2025
Andrew J. RitterDirector––May 29, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Manu Ohri
CFO & Secretary
Aug 11, 2023Award+200,000$0.29$58.00K200,000
Manu Ohri
CFO & Secretary
Aug 11, 2023Other−200,000$0.29$58.00K0
Manu Ohri
CFO & Secretary
Aug 11, 2023Other+200,000$0.29$58.00K300,000
Michael Martin Breen
Executive Chairman/Interim CEO, Director
Aug 11, 2023Award+200,000$0.29$58.00K856,218
Michael Martin Breen
Executive Chairman/Interim CEO, Director
Apr 11, 2023Buy+50,000$0.50$25.00K656,218
Manu Ohri
CFO & Secretary
Apr 6, 2023Buy+50,000$0.50$25.00K50,000
Manu Ohri
CFO & Secretary
Jul 15, 2022Other+100,000––100,000
Manu Ohri
CFO & Secretary
Jul 15, 2022Other−100,000––0
Manu Ohri
CFO & Secretary
Jul 15, 2022Award+100,000––100,000
Michael Martin Breen
Exec. Chair. and Interim CEO, Director
Jul 15, 2022Award+278,058––606,218
Michael Martin Breen
Director
Feb 25, 2021Conversion+40,243$3.40$136.83K318,301
Michael Martin Breen
Director
Feb 25, 2021Conversion+9,859$3.40$33.52K328,160
Gregory Berk
Director
Feb 16, 2021Award+278,058––278,058
Michael Martin Breen
Director
Feb 16, 2021Award+278,058––278,058
Bruce Wendel
Director
Feb 16, 2021Award+347,572––352,655
Bruce Wendel
Director
Dec 22, 2020Buy+1,374$8.87$12.19K4,642
Bruce Wendel
Director
Dec 22, 2020Buy+441$8.73$3.85K5,083
Steven W. Weldon
–
Dec 22, 2020Sale(10b5-1 plan)−47,978$0.40$19.19K3,720,000
Steven W. Weldon
–
Dec 21, 2020Sale(10b5-1 plan)−35,722$0.34$12.15K3,767,978
Steven W. Weldon
–
Dec 21, 2020Sale(10b5-1 plan)−50,000$0.30$15.00K3,853,700
Steven W. Weldon
–
Dec 21, 2020Sale(10b5-1 plan)−50,000$0.33$16.50K3,803,700
Steven W. Weldon
–
Dec 18, 2020Sale(10b5-1 plan)−50,000$0.30$15.00K3,903,700
Steven W. Weldon
–
Dec 17, 2020Sale(10b5-1 plan)−50,000$0.31$15.50K3,953,700
Steven W. Weldon
–
Dec 17, 2020Sale(10b5-1 plan)−50,000$0.30$15.00K4,003,700
Steven W. Weldon
–
Dec 16, 2020Sale(10b5-1 plan)−50,000$0.30$15.00K4,053,700
Steven W. Weldon
–
Dec 15, 2020Sale(10b5-1 plan)−50,000$0.30$15.00K4,153,700
Steven W. Weldon
–
Dec 15, 2020Sale(10b5-1 plan)−50,000$0.30$15.00K4,203,700
Steven W. Weldon
–
Dec 15, 2020Sale(10b5-1 plan)−50,000$0.32$16.00K4,103,700
Steven W. Weldon
–
Dec 14, 2020Sale(10b5-1 plan)−50,000$0.28$14.00K4,350,000
Steven W. Weldon
–
Dec 14, 2020Sale(10b5-1 plan)−46,300$0.29$13.43K4,253,700
Steven W. Weldon
–
Dec 14, 2020Sale(10b5-1 plan)−50,000$0.29$14.50K4,300,000
Steven W. Weldon
–
Dec 11, 2020Sale(10b5-1 plan)−50,000$0.25$12.50K4,450,000
Steven W. Weldon
–
Dec 11, 2020Sale(10b5-1 plan)−50,000$0.26$13.00K4,400,000
Bruce Wendel
Director
Nov 16, 2020Buy+3,268$3.14$10.26K3,268
Tony Cataldo
CEO, Director, 10% owner
Jun 2, 2020Sale−4,234,320––6,500,000
Steven W. Weldon
CFO, Director
May 13, 2020Sale−2,269,708––4,500,000
Steven W. Weldon
CFO, Director, 10% owner
Aug 14, 2019Award+4,500,000––6,769,707
Tony Cataldo
CEO, Director, 10% owner
Aug 14, 2019Award+7,000,000––10,734,320
Tony Cataldo
Director
Feb 6, 2019Sale−800,000––4,029,600
Raymond W. Urbanski
CEO, Director
Feb 1, 2019Sale−176,980––1,351,918
Tony Cataldo
Executive Chairman, Director, 10% owner
Nov 2, 2017Gift−100,000––4,843,029
Tony Cataldo
Executive Chairman, Director, 10% owner
Nov 2, 2017Gift−3,000,000––1,843,029
Tony Cataldo
Executive Chairman, Director, 10% owner
Nov 2, 2017Gift−200,000––4,943,029
Steven W. Weldon
CFO, Director
Sep 1, 2017Award+2,566,835––2,568,840
Tony Cataldo
Executive Chairman, Director, 10% owner
Sep 1, 2017Award+5,129,660––5,143,029
Investment Fund Ltd Bristol
10% owner
Apr 5, 2016Other+250,000––463,806
Investment Fund Ltd Bristol
10% owner
Apr 4, 2016Sale−675,000$303750.00$205.03B1,525,472
Theorem Group, LLC
10% owner
Dec 27, 2010Sale−360,100$0.13$46.81K0
Anshuman Dube
Director, 10% owner
Dec 27, 2010Sale−360,100$0.13$46.81K0
Theorem Group, LLC
10% owner
Dec 23, 2010Sale−339,900$0.13$44.19K360,100
Theorem Group, LLC
10% owner
Dec 23, 2010Conversion+700,000$0.05$35.00K700,000
Anshuman Dube
Director, 10% owner
Dec 23, 2010Conversion+700,000$0.05$35.00K700,000
Anshuman Dube
Director, 10% owner
Dec 23, 2010Sale−339,900$0.13$44.19K360,100
Gary M. Post
–
Aug 31, 2010Sale−69,600$0.11$7.66K900,000
Gary M. Post
–
Aug 30, 2010Sale−30,940$0.11$3.40K969,600
Gary M. Post
–
Aug 26, 2010Sale−76,060$0.12$9.13K1,000,540
Gary M. Post
Secretary, Director
Jul 8, 2010Sale−50,000$0.11$5.50K1,076,600
Gary M. Post
Secretary, Director
Jul 7, 2010Sale−25,000$0.11$2.75K1,375,000
Gary M. Post
Secretary, Director
Jul 7, 2010Sale−100,000$0.11$11.00K1,400,000
Gary M. Post
Secretary, Director
Jul 7, 2010Sale−33,400$0.11$3.67K1,341,600

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.56%
0M shares short
Days to cover
3.2
At 0M shares a day
Change since last report
-11.6%
From 0M shares
Short volume, 20 days
50.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of GT Biopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 42,579 shares on Sep 14, 2026 over the last 90 days.

See a number that looks wrong?